Langlui's Big Board and Options Plays

[Abondanceinvest]

Sept 27 Healthcare Conference_NEPT_([/b]3.16)_5-7.00 target!! short term

NEPTUNE TECH & BIORESOURCES ORD
Symbol U : NEPT
Recent Sedar Documents
Acasti Pharma to Present at JMP Healthcare Conference

2011-09-21 08:30 ET - News Release


LAVAL, Quebec, Sept. 21, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (TSX-V:APO), a Neptune Technologies & Bioressources Inc. ("Neptune") subsidiary, announces it will present at the 2011 JMP Securities Healthcare Conference :

The JMP Securities Healthcare Conference

Tuesday, September 27, 2011
12:00 PM Eastern Time
The St. Regis Hotel, New York
Speaker : Harlan Waksal, M.D., Executive Vice-President, Business & Scientific Affairs

For more information about this conference please visit : http://www.jmpg.com/jmpsecurities/about/conferences/

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc.(Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.


Neptune Penetrates Asia by Partnering With Chinese SKFC, the World's Largest Fleet Owner of Fishing Vessels

2011-09-19 08:00 ET - News Release


LAVAL, Quebec, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX-V:NTB) announces the conclusion of a Memorendum of Understanding (MOU) with Shanghai KaiChuang Deep Sea Fisheries Co., Ltd. (SKFC) (together the "Parties") to form a 50%/50% Joint Venture named Neptune-SKFC Biotechnology that will manufacture and commercialize Neptune's krill products in Asia, the world's largest market for such products.

The initial cost of the project will reach up to USD $30,000,000 (financed be Chinese Banks and the Parties)

to realize the construction of a state of the art production facility using Neptune Proprietary Production Technology in China as well as for immediately developing a strong commercial distribution network for Asia. According to the agreement, SKFC will supply all the raw material and Neptune will provide a license to Neptune-SKFC Biotechnology allowing it rights of use of its Production Technology IP for the Asian Market in return of a significant up front payment as well as for royalty payments.

''We are extremely pleased to partner with Neptune as it is the desire of the Chinese government to develop value-added products from primary fishing industry'' stated Tang Qiqing, Chairman of the Board of SKFC.

''After evaluating different Companies in the krill oil business, it became obvious to us that Neptune had the best Proprietary Production Technology and IP protection and became our preferred choice. We are pleased to have concluded this MOU as both parties negotiated in the best interest of their respective shareholders'' stated Zhou Jinwang, Director of the Board of SKFC.

''This major milestone was part of SKFC's development plan in order to become the world's largest krill fishing company. This partnership should generate production and sales of up to 500MT of krill oil over the next five years.'' stated Xie Feng, Chief Executive Officer of SKFC.

About the Chinese Market